Introduction {#s1}
============

Based on the GLOBOCAN2012 investigations, oral carcinoma is regarded as one of the most common causes of cancer related morbidity and mortality, contributing to 3.8% of all cancer cases and 3.6% of cancer related deaths (Warnakulasuriya, [@B60]; Ferlay et al., [@B17]; Shield et al., [@B47]). The long-term survival rate of oral carcinoma is \< 50% despite improved treatment schedules such as surgery, radiation and chemotherapy (Coleman et al., [@B10]; De Angelis et al., [@B12]). Oral carcinoma is highly associated with tobacco smoking, alcohol consumption and the exposure to a variety of exogenous or endogenous carcinogens (Petti, [@B41]). However, the etiology of oral carcinoma remains poorly understood. Furthermore, not all individuals exposing to these risk factors are subject to oral carcinoma, and additional genetic factors may also contribute to oral carcinoma susceptibility (Chen et al., [@B8]; Anantharaman et al., [@B2]; Niu et al., [@B38]).

The human TP53 is well-known tumor suppressor gene and plays an important role in DNA damage response by inducing cell cycle arrest or apoptosis (Slee et al., [@B50]; Harris and Levine, [@B18]). TP53 mutation is frequently found in human tumors, including oral carcinoma (Olivier et al., [@B39]). A common single nucleotide polymorphism at TP53 codon 72 is crucial for its tumor suppressor function (Suzuki and Matsubara, [@B53]). Several meta-analysis demonstrated that TP53 codon 72 polymorphism was associated with the susceptibility to a variety of cancers, such as colorectal cancer (Du et al., [@B15]), esophageal cancer (Steccanella et al., [@B51]), nasopharyngeal cancer (Zhuo et al., [@B67]), and non-Hodgkin lymphomas (Xu et al., [@B63]).

Själander et al. demonstrated that the distribution of TP53 genotypes differed among different ethnicities, which is a notable confounding factor in carcinoma risk (Själander et al., [@B49]). Tobacco and alcohol use are known risk factors for oral carcinoma (Hashibe et al., [@B19]). In addition, TP53 codon 72 mutation spectrum has been shown to be altered with Human papillomavirus (HPV) infection, an emerging oral carcinoma risk factor (Chor et al., [@B9]). So far many case-control studies investigated the association of functional polymorphism of TP53 codon 72 with susceptibility to oral carcinoma, but the results remain conflicting and inconclusive (Tandle et al., [@B54]; Nagpal et al., [@B37]; Hsieh et al., [@B21]; Wang et al., [@B59]; Saleem et al., [@B44]). We therefore conducted this meta-analyses to evaluate the relationship of TP53 codon 72 polymorphism with tobacco and/or alcohol use and HPV infection in the susceptibility to oral carcinoma.

Materials and methods {#s2}
=====================

Search strategy
---------------

PubMed, EMBASE, and Google of Scholar databases up to August 19, 2017 were searched with a combination of the keywords as follows: \[(oral OR tongue OR mouth OR buccal OR oropharynx) AND (tumor OR carcinoma OR cancer) AND (TP53 OR P53 OR Arg72Pro) AND (variant^\*^ OR mutation OR polymorphism^\*^)\].

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were: (i) evaluated the association between tobacco and/or alcohol uses, TP53 codon 72 polymorphism, HPV infection, and susceptibility to oral carcinoma; (ii) case-control researches published in English or Chinese; (iii) definite histopathologic diagnosis or clearly reported the type; (iv) sufficient data to evaluate the ORs and 95%CI, and *P*-value; (v) genotype distribution was in Hardy-Weinberg equilibrium (HWE). Major exclusion criteria were: (i) Reviews, conference abstracts, case reports; (ii) only-case study; (iii) genotype distribution was inconsistent with HWE; (iv) when duplicated studies published, only the study with the large sample size was included.

Data extraction
---------------

Data extraction was performed independently by two authors using a standardized form. Data such as: first author, country, ethnicity, year of publication, source of the controls, genotype distribution of cases and controls. Discrepancies were settled by discussion, with disagreements resolved by consensus.

Statistical analysis
--------------------

The association was determined by calculating odds ratios (ORs) with corresponding 95% credible interval (95%CI). *Q*-test and *I*^2^ statistics were used to quantify statistical heterogeneity. The random-effect model was conducted if the heterogeneity was significant (*P* \< 0.05) (DerSimonian and Laird, [@B13]); otherwise, the fixed effect model was utilized (Mantel and Haenszel, [@B32]). The sensitivity analysis was carried out through sequential exclusion of any one individual study. Begg\'s funnel plot and the Egger\'s test was performed to assess the potential publication bias of the researches (Begg and Mazumdar, [@B6]; Egger et al., [@B16]). The present meta-analysis was carried out by STATA 12.0 (Stata, College Station, TX, USA). *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of the selected studies
---------------------------------------

The selection of eligible studies to be included in this meta-analysis was shown in Figure [1](#F1){ref-type="fig"}, 905 potentially relevant researches were initially obtained from the PubMed, EBMASE, and Google of Scholar databases. After the exclusion of irrelevant studies, a total of 28 studies were included. Among the remaining articles, four articles (Tandle et al., [@B54]; Jing et al., [@B24]; Saleem et al., [@B44]; Nagam et al., [@B36]) were not in agreement with HWE (*P* \< 0.001) and three duplicated data publications were further excluded (Ji et al., [@B23]; Misra et al., [@B34]; Wang et al., [@B59]). We included 21 case-control study involving 3,525 oral carcinoma patients and 3,712 controls (Summersgill et al., [@B52]; Drummond et al., [@B14]; Nagpal et al., [@B37]; Shen et al., [@B46]; Katiyar et al., [@B25]; Kietthubthew et al., [@B27]; Hsieh et al., [@B21]; Mitra et al., [@B35]; Bau et al., [@B5]; Kuroda et al., [@B29]; Chen et al., [@B7]; Lin et al., [@B31]; Tu et al., [@B56]; Kitkumthorn et al., [@B28]; Ihsan et al., [@B22]; Saini et al., [@B43]; Patel et al., [@B40]; Adduri et al., [@B1]; Sina et al., [@B48]; Rao et al., [@B42]; Zarate et al., [@B65]). The characteristics of the selected studies are shown in Table [1](#T1){ref-type="table"}.

![Flow diagram of the publication selection process.](fphys-09-01014-g0001){#F1}

###### 

Main characteristics of studies included in the meta-analysis.

  **Author**     **Year**   **Country**   **Ethnicity**   **Control source**   **Genotyping methods**   **Case**   **Control**   **HWE**                    
  -------------- ---------- ------------- --------------- -------------------- ------------------------ ---------- ------------- --------- ----- ----- ---- --------
  Adduri         2014       India         Asian           HP                   PCR                      23         48            44        31    53    26   0.7185
  Patel          2013       India         Asian           HP                   PCR-RFLP                 32         29            18        30    58    22   0.5281
  Kietthubthew   2003       Thailand      Asian           PB                   PCR                      32         44            21        35    34    28   0.0036
  Nagpal         2002       India         Asian           PB                   PCR                      31         58            21        13    11    2    0.0876
  Mitra          2005       India         Asian           HP                   PCR                      87         155           66        85    159   98   0.2031
  Sina           2014       Iran          Asian           HP                   PCR                      20         25            10        40    48    12   0.6769
  Ihsan          2011       India         Asian           PB                   PCR                      30         63            23        63    143   72   0.6186
  Chen           2008       USA           Caucasian       PB                   PCR-RFLP                 183        121           22        181   144   24   0.5182
  Zarate         2017       Argentine     Caucasian       HP                   PCR                      12         23            9         13    3     2    0.0471
  Bau            2007       China         Asian           HP                   PCR                      46         70            21        18    65    22   0.014
  Katiyar        2003       India         Asian           HP                   PCR                      10         24            10        5     12    3    0.3428
  Saini          2010       Malaysia      Asian           PB                   PCR                      22         40            37        28    39    23   0.2152
  Rao            2017       India         Asian           PB                   PCR                      35         110           59        46    112   54   0.1814
  Lin            2008       China         Asian           PB                   PCR                      96         155           46        72    152   56   0.1352
  Kuroda         2007       Japan         Asian           HP                   PCR-RFLP                 41         44            15        109   117   45   0.1591
  Summersgill    2000       USA           Mixed           HP                   PCR-CTPP                 102        70            18        168   112   28   0.1436
  Shen-a         2002       USA           Caucasian       PB                   PCR-RFLP                 55         41            9         175   134   24   0.8107
  Shen-b         2002       USA           Caucasian       PB                   PCR-RFLP                 66         47            8         175   134   24   0.8107
  Tu             2008       China         Asian           PB                   DNAsequence              53         106           30        41    60    15   0.3367
  Drummond       2002       Brazil        Mixed           NR                   PCR                      31         45            6         33    45    4    0.0212
  Kitkumthorn    2010       Thailand      Asian           PB                   PCR-RFLP                 35         40            3         27    47    20   0.9569
  Hsieh-a        2005       China         Asian           PB                   PCR-RFLP                 149        274           100       128   177   66   0.7229
  Hsieh-b        2005       China         Asian           PB                   PCR-RFLP                 38         54            14        128   177   66   0.7229

*PB, population-based; HB, hospital-based; HWE, Hardy-Weinberg equilibrium; NR, no report*.

Meta-analysis results
---------------------

Based on 21 case-control studies no significant association was found between TP53 Arg72Pro polymorphism and susceptibility to oral carcinoma in any genetic model (ArgPro vs. ArgArg: OR = 1.0, 95%CI = 0.90--1.11; ProPro vs. ArgArg: OR = 0.97, 95%CI = 0.84--1.12; Pro vs. Arg: OR = 1.0, 95%CI = 0.90--1.12; ArgPro+ProPro vs. ArgArg: OR = 1.01, 95%CI = 0.86--1.18; ProPro vs. ArgPro+ArgArg: OR = 0.96, 95% = 0.85--1.09). Based on subgroup analysis, stratified by control source or ethnicity, we obtained similar results (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![Forest plots demonstrated the association between TP53 codon 72 polymorphism and oral carcinoma susceptibility in the allele model. **(A)** Overall analysis. **(B)** Subgroup analysis by source of control.](fphys-09-01014-g0002){#F2}

###### 

Meta-analysis of the association between TP53 codon 72 polymorphism and oral carcinoma susceptibility.

  **Comparison**             **Subgroup**   **Studies**   **Heterogeneity test**   **Association test**   **Model**           **Publication bias**       
  -------------------------- -------------- ------------- ------------------------ ---------------------- ------------------- ---------------------- --- -------
  Pro vs. Arg                Overall        21            0                        60.4                   1.00 (0.90--1.12)   0.953                  R   0.16
                             PB             13            0.002                    60.9                   0.99 (0.86--1.14)   0.898                  R   
                             HP             9             0.002                    67.1                   1.03 (0.82--1.30)   0.779                  R   
                             Caucasian      4             0.039                    64.3                   1.07 (0.78--1.47)   0.662                  R   
                             Asian          17            0                        65.8                   0.99 (0.86--1.14)   0.867                  R   
  ArgPro vs. ArgArg          Overall        21            0.03                     39                     1.00 (0.90--1.11)   0.991                  F   0.355
                             PB             13            0.241                    20.1                   1.04 (0.90--1.21)   0.59                   R   
                             HB             9             0.011                    59.8                   0.93 (0.67--1.29)   0.661                  R   
                             Caucasian      4             0.024                    68.3                   1.08 (0.69--1.69)   0.742                  R   
                             Asian          17            0.052                    38.9                   0.98 (0.84--1.19)   0.999                  R   
  ProPro vs. ArgArg          Overall        21            0.001                    54.4                   0.97 (0.84--1.12)   0.997                  R   0.399
                             PB             13            0.005                    57.8                   0.98 (0.73--1.32)   0.889                  R   
                             HB             9             0.015                    57.8                   1.02 (0.68--1.55)   0.913                  R   
                             Caucasian      4             0.317                    15                     1.09 (0.68--1.73)   0.722                  R   
                             Asian          17            0                        63.5                   0.96 (0.72--1.28)   0.775                  R   
  ArgPro+ProPro vs. ArgArg   Overall        21            0.001                    53.8                   1.01 (0.86--1.18)   0.914                  R   0.266
                             PB             13            0.028                    47.7                   1.03 (0.86--1.23)   0.752                  R   
                             HB             9             0.002                    66.4                   0.98 (0.70--1.37)   0.913                  R   
                             Caucasian      4             0.013                    72.2                   1.12 (0.71--1.77)   0.611                  R   
                             Asian          17            0.002                    56.2                   0.99 (0.82--1.20)   0.961                  R   
  ProPro vs. ArgArg+ArgPro   Overall        21            0.033                    38.4                   0.96 (0.85--1.09)   0.521                  F   0.356
                             PB             13            0.046                    43.6                   0.94 (0.81--1.10)   0.461                  F   
                             HB             9             0.084                    42.6                   0.98 (0.79--1.21)   0.846                  F   
                             Caucasian      4             0.82                     0                      1.06 (0.71--1.59)   0.77                   R   
                             Asian          17            0.005                    52.9                   0.97 (0.78--1.20)   0.761                  R   

*OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not available; PB, population-based; HB, hospital-based*.

In addition, subgroup analysis stratified by tobacco use (no vs. yes) was performed, and the association was still not significant in either tobacco users (OR = 0.88, 95%CI = 0.67--1.16) or non-users (OR = 0.84, 95%CI = 0.84--2.26). Similar results were found for subgroup analysis stratified by alcohol use or HPV infection status (Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

![Forest plots demonstrated the association between TP53 codon 72 polymorphism and oral carcinoma susceptibility in the allele model. **(A)** Subgroup analysis by tobacco users. **(B)** Subgroup analysis by alcohol users.](fphys-09-01014-g0003){#F3}

![Forest plots demonstrated the association between TP53 codon 72 polymorphism and oral carcinoma susceptibility stratified by HPV infection status in the allele model.](fphys-09-01014-g0004){#F4}

###### 

Meta-analysis of the association between TP53 codon 72, tobacco or alcohol uses, HPV-infection status and Oral carcinoma susceptibility.

  **Comparison**             **Subgroup**           **Studies**   **Heterogeneity test**   **Association test**   **Model**           **Publication bias**       
  -------------------------- ---------------------- ------------- ------------------------ ---------------------- ------------------- ---------------------- --- -------
  Pro vs. Arg                Overall                21            0                        60.4                   1.00 (0.90--1.12)   0.953                  R   0.16
                             Tobacco users          5             0.035                    61.2                   1.00 (0.73--1.36)   0.992                  R   
                             Non-users of tobacco   3             0.12                     52.8                   1.02 (0.65--1.60)   0.922                  R   
                             Alcohol users          2             0.754                    0                      1.05 (0.81--1.35)   0.729                  F   
                             Non-users of alcohol   2             0.323                    0                      0.90 (0.60--1.35)   0.62                   F   
                             HPV infection          4             0.482                    0                      1.00 (0.75--1.34)   0.986                  F   
  ArgPro vs. ArgArg          Overall                21            0.03                     39                     1.00 (0.90--1.11)   0.991                  F   0.355
                             Tobacco users          5             0.215                    30.9                   0.88 (0.67--1.16)   0.382                  F   
                             Non-users of tobacco   3             0.269                    23.8                   1.38 (0.84--2.26)   0.201                  F   
                             Alcohol users          2             0.37                     0                      1.13 (0.80--1.60)   0.482                  F   
                             Non-users of alcohol   2             0.939                    0                      0.93 (0.51--1.68)   0.807                  F   
                             HPV infection          4             0.514                    0                      0.90 (0.58--1.42)   0.658                  F   
  ProPro vs. ArgArg          Overall                21            0.001                    54.4                   0.97 (0.84--1.12)   0.997                  R   0.399
                             Tobacco users          5             0.045                    58.9                   1.02 (0.55--1.90)   0.953                  R   
                             Non-users of tobacco   3             0.227                    32.7                   0.99 (0.46--2.10)   0.972                  R   
                             Alcohol users          2             0.813                    0                      1.04 (0.55--1.97)   0.913                  F   
                             Non-users of alcohol   2             0.305                    4.8                    0.86 (0.38--1.91)   0.704                  F   
                             HPV infection          4             0.576                    0                      1.01 (0.55--1.85)   0.971                  F   
  ArgPro+ProPro vs. ArgArg   Overall                21            0.001                    53.8                   1.01 (0.86--1.18)   0.914                  R   0.266
                             Tobacco users          7             0.139                    38                     0.87 (0.70--1.08)   0.196                  F   
                             Non-users of tobacco   5             0.201                    33.1                   1.00 (0.70--1.44)   0.985                  F   
                             Alcohol users          2             0.474                    0                      1.11 (0.80--1.54)   0.548                  F   
                             Non-users of alcohol   2             0.666                    0                      0.91 (0.53--1.57)   0.73                   F   
                             HPV infection          4             0.351                    9.7                    1.20 (0.87--1.64)   0.267                  F   
  ProPro vs. ArgArg+ArgPro   Overall                21            0.033                    38.4                   0.96 (0.85--1.09)   0.521                  F   0.356
                             Tobacco users          5             0.167                    38.2                   0.94 (0.70--1.27)   0.7                    F   
                             Non-users of tobacco   3             0.501                    0                      0.83 (0.51--1.33)   0.435                  F   
                             Alcohol users          2             0.888                    0                      0.92 (0.50--1.67)   0.779                  F   
                             Non-users of alcohol   2             0.248                    24.9                   0.84 (0.40--1.78)   0.657                  F   
                             HPV infection          4             0.237                    29.2                   1.09 (0.66--1.81)   0.73                   F   

*OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not available; PB, population-based; HB, hospital-based*.

Sensitivity and heterogeneity analysis
--------------------------------------

Between-study heterogeneity was examined and significant heterogeneity (*P* \< 0.05) was detected in some genetic comparisons, so random-effects model was adopted (DerSimonian and Laird, [@B13]); otherwise, the fixed-effect model was utilized (Mantel and Haenszel, [@B32]). The sensitivity analysis was carried out through sequential exclusion of any one individual study, and the results showed that our conclusion was robust and credible (Figure [5](#F5){ref-type="fig"}).

![Sensitivity analysis for the influences of TP53 codon 72 polymorphism and oral carcinoma susceptibility under the allele model. **(A)** Overall analysis. **(B)** Subgroup analysis by tobacco users.](fphys-09-01014-g0005){#F5}

Publication bias
----------------

Begg\'s and Egger\'s test was utilized to examine the potential publication bias of the studies (Begg and Mazumdar, [@B6]; Egger et al., [@B16]). As shown in Figure [6](#F6){ref-type="fig"}, there was no significant publication bias (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

![Funnel plot of publication biases on the association between TP53 codon 72 polymorphism and oral carcinoma susceptibility.](fphys-09-01014-g0006){#F6}

Discussion
----------

TP53 inactivation is a frequent event in cancer and involves point mutations and allelic loss (Baker et al., [@B4]; Tommasino et al., [@B55]). Moreover, TP53 polymorphisms could affect cancer susceptibility (Whibley et al., [@B61]). Pro72 allele has been implicated in coronary artery disease (Khan et al., [@B26]), systemic lupus erythematosus (Lee et al., [@B30]) and ulcerative colitis (Vaji et al., [@B57]). In contrast, Arg72 allele is implicated in pilocytic astrocytoma (Mascelli et al., [@B33]). Codon 72 TP53 polymorphisms have shown different associations with the risk of carcinomas in different populations, including oral carcinoma susceptibility (Tandle et al., [@B54]; Nagpal et al., [@B37]; Hsieh et al., [@B21]; Wang et al., [@B59], [@B58]; Dahabreh et al., [@B11]; Saleem et al., [@B44]).

Although many case-control studies investigated the association of tobacco and/or alcohol uses, TP53 codon 72 polymorphism, and HPV infection with oral carcinoma susceptibility, the results were inconclusive. A past case-control studies failed to detect any significant association of TP53 codon 72 polymorphism with oral carcinoma susceptibility (Summersgill et al., [@B52]). In 2007, Bau et al. reported that the ArgArg genotype seemed to increase the susceptibility to oral carcinoma 2.7-fold in Chinese (Bau et al., [@B5]). Previous several meta-analyses reported the lack of association between TP53 codon 72 polymorphism and the risk of oral carcinoma (Zhuo et al., [@B68]; Zeng et al., [@B66]; Hou et al., [@B20]), but these studies did not stratify the conditions such as tobacco and/or alcohol uses, HPV-infection status to perform subgroup analysis. Therefore, we performed the present meta-analysis to provide better estimate on the association of TP53 codon 72 polymorphism with oral carcinoma susceptibility.

Tobacco smoking is a well-known risk factor of cancer and could affect gene polymorphism in oral carcinoma (Ye et al., [@B64]). To evaluate the association between TP53 polymorphism and oral carcinoma susceptibility in tobacco users, we analyzed all available data extracted from the included studies, and found no significant association, indicating that TP53 codon 72 polymorphism is not a potential risk factor of oral carcinoma in tobacco users.

Regular alcohol consumption is associated with an increased risk for oral cancer. Such association is dose-dependent. Indeed, among individuals consuming 4--5 drinks daily, the risk for cancer of the oral cavity is 2--3-fold higher than among non-drinkers (Baan et al., [@B3]; Seitz and Stickel, [@B45]; Wiseman, [@B62]). To further investigate a possible association between oral carcinoma susceptibility and TP53 codon 72 polymorphism in alcohol users, we extracted relevant data from two studies and the results also failed to suggest a market correlation, demonstrated that TP53 codon 72 polymorphism may not be a risk of oral carcinoma in alcohol use status.

HPV infection has been suggested as one of the contributing factors for oral carcinoma. It was suggested that the interaction of TP53 codon 72 polymorphism with HPV was associated with oral carcinoma susceptibility (Kitkumthorn et al., [@B28]). However, this opinion was challenged by other studies (Summersgill et al., [@B52]; Lin et al., [@B31]). In this study we performed subgroup analysis on the interaction of p53 gene polymorphism with HPV infection on oral cancer susceptibility and the results indicated that TP53 codon 72 polymorphism is not a risk factor of oral carcinoma no matter HPV infection status.

The present study had several limitations. Firstly, only studies written in English or Chinese were included in the meta-analysis. This means that eligible studies published in other languages may have been overlooked, which may have introduced selection bias. Secondly, the sample size of some studies was limited and the results should be interpreted carefully. Thirdly, this study had statistical heterogeneity, although this is extremely common in meta-analyses of genetic association studies. We thus conducted subgroup analyses to identify all factors that contribute to the heterogeneity. Finally, other factors such as the age, gender, life-style that may affect the interaction of TP53 codon 72 polymorphism with oral carcinoma could not be analyzed due to the lack of original data.

In summary, this meta-analysis suggests that there is no statistical association between TP53 codon 72 polymorphism and oral cancer susceptibility, independent of tobacco and/or alcohol use and HPV-infection status. However, this conclusion should be confirmed by multi-center and large-scale studies based on multiple ethnic groups.
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